FDA Approves Galderma’s IL-31 Blocker for PN
The U.S. Food and Drug Administration (FDA) has approved nemolizumab (Nemluvio, Galderma) as a pre-filled pen for subcutaneous injection for the treatment of adults with prurigo nodularis. Nemolizumab specifically inhibits interleukin (IL)-31 cytokine signaling, which is known to drive itch and is involved in inflammation, altered epidermal differentiation, and fibrosis in prurigo nodularis. Nemolizumab was […]